Death by Opioids: Are there non-addictive scientific solutions?

B William Downs, Kenneth Blum, David Baron, Abdalla Bowirrat, Lisa Lott, Raymond Brewer, Brent Boyett, David Siwicki, A Kenison Roy, Arwen Podesta, Sampada Badgaiyan, Raju Hajela, Lyle Fried, Rajendra D Badgaiyan
{"title":"Death by Opioids: Are there non-addictive scientific solutions?","authors":"B William Downs,&nbsp;Kenneth Blum,&nbsp;David Baron,&nbsp;Abdalla Bowirrat,&nbsp;Lisa Lott,&nbsp;Raymond Brewer,&nbsp;Brent Boyett,&nbsp;David Siwicki,&nbsp;A Kenison Roy,&nbsp;Arwen Podesta,&nbsp;Sampada Badgaiyan,&nbsp;Raju Hajela,&nbsp;Lyle Fried,&nbsp;Rajendra D Badgaiyan","doi":"10.15761/JSIN.1000211","DOIUrl":null,"url":null,"abstract":"<p><p>In the face of the current Opioid crisis in America killing close to 800,000 people since 2004, we are proposing a novel approach to assist in at least attenuating these unwanted premature deaths. While we applaud the wonderful efforts of our governmental institutes and professional societies (NIDA, NIAAA, ASAM, ABAM ) in their extraordinary efforts in combating this continued dilemma, the current approach is failing, and other alternative approaches should at least be tested. These truths present a serious ethical dilemma to scientists, clinicians and counselors in the Reward Deficiency Syndrome (RDS) treatment community. It is important to realize that the current DSM-5 does not actually accurately display the natural brain reward process. The human brain has not been designed to carve out specific drugs like opioids, alcohol, nicotine, cocaine, benzodiazepines or cannabis and process addictions such as gambling as distinct endophenotypes. This is true in spite of natural ligands for cannabinoids, endorphins, or even benzodiazepines. The most accurate endophenotype is indeed reward dysfunction (e.g hypodopaminergic or hyperdopaminergic). With this mind, we are hereby proposing that the current Medication Assisted Treatment (i.e. 'MAT') expands to needed individuals as an initial \"Band-Aid\" to reduce harm avoidance, with the long-term goal of prophylaxis. So, to be clear, there may be other promising modalities other than MAT such as repetitive transcranial magnetic stimulation (rTMS), exercise and even new medications with positive allosteric modulators of GABA-A receptors, as well as the highly researched Genetic Addiction Risk Score (GARS) coupled with precision KB220Z. This will induce \"dopamine homeostasis\" to effectively rebalance and restore healthier brain function by promoting the cross talk between various brain regions (e.g. Nucleus accumbens, cingulate gyrus, hippocampus etc.) resulting in dopamine homeostasis. Our laudable goal is to not only save lives, but to redeem joy and improve the quality of life in the recovery community through scientifically sound natural non-addicting alternatives.</p>","PeriodicalId":87318,"journal":{"name":"Journal of systems and integrative neuroscience","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2019-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6904107/pdf/nihms-1059030.pdf","citationCount":"16","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of systems and integrative neuroscience","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.15761/JSIN.1000211","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2019/10/31 0:00:00","PubModel":"Epub","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 16

Abstract

In the face of the current Opioid crisis in America killing close to 800,000 people since 2004, we are proposing a novel approach to assist in at least attenuating these unwanted premature deaths. While we applaud the wonderful efforts of our governmental institutes and professional societies (NIDA, NIAAA, ASAM, ABAM ) in their extraordinary efforts in combating this continued dilemma, the current approach is failing, and other alternative approaches should at least be tested. These truths present a serious ethical dilemma to scientists, clinicians and counselors in the Reward Deficiency Syndrome (RDS) treatment community. It is important to realize that the current DSM-5 does not actually accurately display the natural brain reward process. The human brain has not been designed to carve out specific drugs like opioids, alcohol, nicotine, cocaine, benzodiazepines or cannabis and process addictions such as gambling as distinct endophenotypes. This is true in spite of natural ligands for cannabinoids, endorphins, or even benzodiazepines. The most accurate endophenotype is indeed reward dysfunction (e.g hypodopaminergic or hyperdopaminergic). With this mind, we are hereby proposing that the current Medication Assisted Treatment (i.e. 'MAT') expands to needed individuals as an initial "Band-Aid" to reduce harm avoidance, with the long-term goal of prophylaxis. So, to be clear, there may be other promising modalities other than MAT such as repetitive transcranial magnetic stimulation (rTMS), exercise and even new medications with positive allosteric modulators of GABA-A receptors, as well as the highly researched Genetic Addiction Risk Score (GARS) coupled with precision KB220Z. This will induce "dopamine homeostasis" to effectively rebalance and restore healthier brain function by promoting the cross talk between various brain regions (e.g. Nucleus accumbens, cingulate gyrus, hippocampus etc.) resulting in dopamine homeostasis. Our laudable goal is to not only save lives, but to redeem joy and improve the quality of life in the recovery community through scientifically sound natural non-addicting alternatives.

Abstract Image

阿片类药物致死:是否有不上瘾的科学解决方案?
自2004年以来,美国目前的阿片类药物危机导致近80万人死亡,面对这种局面,我们提出了一种新方法,至少可以帮助减少这些不受欢迎的过早死亡。虽然我们赞扬我们的政府机构和专业协会(NIDA, NIAAA, ASAM, ABAM)为解决这一持续的困境所做的非凡努力,但目前的方法正在失败,其他替代方法至少应该得到测试。这些事实给奖励缺乏综合征(RDS)治疗界的科学家、临床医生和咨询师带来了一个严重的伦理困境。重要的是要认识到,目前的DSM-5实际上并没有准确地显示自然的大脑奖励过程。人类的大脑并没有被设计成能够分辨出阿片类药物、酒精、尼古丁、可卡因、苯二氮卓类药物或大麻等特定药物,也没有将赌博等成瘾行为处理为独特的内表型。尽管大麻素、内啡肽甚至苯二氮卓类药物都有天然配体,但情况确实如此。最准确的内表型确实是奖励功能障碍(如低多巴胺能或高多巴胺能)。带着这样的想法,我们在此建议目前的药物辅助治疗(即。(MAT)扩展到需要的个人,作为最初的“创可贴”,以减少伤害避免,长期目标是预防。因此,需要明确的是,除了MAT之外,可能还有其他有前景的方式,如重复经颅磁刺激(rTMS)、运动,甚至是含有GABA-A受体阳性变张力调节剂的新药,以及高度研究的遗传成瘾风险评分(GARS)和精确KB220Z。这将诱导“多巴胺稳态”,通过促进大脑各区域(如伏隔核、扣带回、海马等)之间的串扰,导致多巴胺稳态,有效地重新平衡和恢复更健康的大脑功能。我们值得称赞的目标不仅是拯救生命,而且是通过科学合理的、自然的、不让人上瘾的替代品,在康复社区中赎回快乐,提高生活质量。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信